• Aucun résultat trouvé

Combinatorial drug discovery in nanoliter droplets

N/A
N/A
Protected

Academic year: 2021

Partager "Combinatorial drug discovery in nanoliter droplets"

Copied!
7
0
0

Texte intégral

Figure

Fig. 1. Droplets platform for combinatorial drug screening. (A) Compounds, cells, and encoding dyes are emulsified into nanoliter droplets and subsequently pooled
Fig. 2. Characterization of droplet platform performance. (A) To model cross-contamination, we tracked the exchange of the fluorescent dye resorufin (carried by source droplets) to empty droplets (sink droplets, encoded by fluorescein)
Fig. 3. Drug repurposing antibiotic potentiation screen. (A) To measure antibiotic potentiation, we generated three-point dose-response curves for 10 different antibiotics in combination (SI Appendix, Table S1) with 4,160 compounds (each at single concentr
Fig. 4. Validation of hits from primary screen. (A) In eight-point checkerboard assays with E

Références

Documents relatifs

These results are in perfect agreement with the Landauer principle: in a quasi-static process, the mean work or heat required to erase 1 bit of information is ln 2 = 0.693.

A Bayesian dose-finding design for drug combination clinical trials based on the logistic model.. Marie-Karelle Riviere, Ying Yuan, Frédéric Dubois,

Wages, as stated in our paper, we used the POCRM design starting at the lowest dose level, based on current practice in Phase I oncology clinical trial.. The authors

SR 8 -IS-A-HYPERNYM RULE: Any noun compound Arg 1 +Arg 2 made up of Arg 1 whose T(Arg 1 )=Lexical Hierarchy contains the initial part of T(Arg 2 )=Lexical Hierarchy of Arg 2

For any starting point in R d , d ≥ 3, we identify the stochastic dierential equa- tion of distorted Brownian motion with respect to a certain discontinuous Muck- enhoupt A 2

Measure each segment in centimeters.. ©c i2Q0y1N1P nK8urtPal kS3oIfLtRwEa0rmeH 6LxLMCm.o m fAAlQla WrqiNgEhxtts4 drUeOsEeir6vje1dV.J U 0MzavdEeD ewDiRtehI

Combination of High Dose Hypofractionated Radiotherapy with Anti- PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a

Appendix 3 (continued): Overview of initiatives supporting antibiotic R&D InitiativeDescriptionAB R&D incentivesValue chain targetedTimeframeAB R&Dfunding EU